Eton Pharmaceuticals (ETON) to Release Earnings on Tuesday

Eton Pharmaceuticals (NASDAQ:ETON) is anticipated to issue its quarterly earnings data before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $10.53 million for the quarter.

Eton Pharmaceuticals Price Performance

ETON stock opened at $15.58 on Monday. The company has a market capitalization of $405.87 million, a P/E ratio of -70.82 and a beta of 1.37. The business has a 50-day moving average price of $15.33 and a 200 day moving average price of $11.28. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $18.41.

Analyst Ratings Changes

ETON has been the topic of a number of research analyst reports. HC Wainwright boosted their price target on Eton Pharmaceuticals from $17.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. Craig Hallum upped their price objective on Eton Pharmaceuticals from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, B. Riley began coverage on Eton Pharmaceuticals in a research note on Friday, January 10th. They set a “buy” rating and a $21.00 target price for the company.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.